Sept. 14, 2010, 10:31 a.m. EDT
(BUSINESS WIRE) -- CytoGenix, Inc. (Pink sheets: CYGX-News) today announced publication of positive results of a study using CytoGenix's novel liner DNA technology.
CytoGenix reports positive results of an animal study where mice were immunized with CYDBA507, CytoGenix avian influenza vaccine candidate, protected against lethal challenge with avian influenza virus. CYDBA507 is CytoGenix's avian influenza vaccine candidate which built on CytoGenix's synDNA platform and expresses influenza virus type A/H5N1 HA and NA proteins. The ability of CYDBA507 to express HA and NA proteins in human cells was confirmed in laboratory studies.
-snip-
No comments:
Post a Comment